Who are AVELUMAB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DURVALUMAB, Avelumab (MSB0010718C), Pf-06835375, Avelumab first-line maintenance, Pf-06823859, Atezolizumab Injection [Tecentriq].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl3833373.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AVELUMAB — Competitive Intelligence Brief

AVELUMAB (AVELUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Programmed Death Ligand-1 Blocker [EPC].

marketed Programmed Death Ligand-1 Blocker [EPC] PD-L1 Monoclonal antibody Live · refreshed every 30 min

Target snapshot

AVELUMAB (AVELUMAB). Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AVELUMAB TARGET	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Avelumab (MSB0010718C)	avelumab-msb0010718c	Pfizer	marketed	Monoclonal antibody	PD-L1
Pf-06835375	pf-06835375	Pfizer	marketed	Immunotherapy	PD-L1
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Atezolizumab Injection [Tecentriq]	Atezolizumab Injection [Tecentriq]	Nykode Therapeutics ASA	marketed	PD-L1 inhibitor	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Programmed Death Ligand-1 Blocker [EPC] class)

· 2 drugs in this class
AstraZeneca · 1 drug in this class
CHECKPOINT THERAPEUTICS INC · 1 drug in this class
Checkpoint Therapeutics Inc · 1 drug in this class
Merck KGaA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AVELUMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl3833373. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab